Levofloxacin Actavis

Levofloxacin, the active ingredient in Levofloxacin Actavis, is a fluoroquinolone antibiotic presented as a topical ophthalmic solution for ocular (subconjunctival) use. It treats bacterial eye infections such as conjunctivitis and keratitis in adult and pediatric patients when prescribed by a qualified healthcare professional. The drug works by inhibiting bacterial DNA gyrase and topoisomerase IV, halting replication and transcription, which leads to bacterial cell death.

GNH USA supplies Levofloxacin Actavis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levofloxacin Actavis is indicated for bacterial ocular infections, where it targets common pathogens causing eye disease.

- Bacterial conjunctivitis: reduces bacterial load and resolves infection symptoms. - Bacterial keratitis: eradicates causative organisms and promotes corneal healing. - Post‑operative ocular infection: prevents or treats bacterial contamination after eye surgery. - Corneal ulcer: eliminates bacterial pathogens to facilitate ulcer resolution.

Adverse reactions to Levofloxacin Actavis are generally localized to the eye, but systemic effects can occur.

Common Side Effects: - Eye irritation or burning sensation. - Redness of the conjunctiva. - Excessive tearing or watery discharge. - Foreign‑body sensation. - Blurred vision. - Mild eyelid edema.

Serious or Rare Side Effects: - Allergic reactions including anaphylaxis. - Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Worsening of corneal ulcer or perforation. - Tendon rupture or tendonitis. - QT‑interval prolongation leading to arrhythmia. - Severe ocular inflammation or uveitis.

When using Levofloxacin Actavis, clinicians should observe several safety considerations to minimise risk.

- Allergy assessment: confirm no known hypersensitivity to fluoroquinolones. - Indication verification: prescribe only for confirmed bacterial ocular infection. - Systemic exposure monitoring: advise patients to report tendon pain or swelling. - Cardiac risk: avoid in patients with known QT prolongation or taking other QT‑prolonging drugs. - Pregnancy and lactation: use only if benefit outweighs potential risk, as safety data are limited. - Store at below 25°C: keep in original packaging, protect from moisture and light.

Levofloxacin Actavis may interact with other medicines, affecting safety or efficacy.

Major Interactions (Avoid): - Concurrent systemic fluoroquinolone therapy: additive toxicity and increased risk of tendon rupture. - Co‑administration with drugs that prolong QT interval (e.g., macrolides, antiarrhythmics): heightened risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - Topical NSAID eye drops: may increase ocular irritation. - Corticosteroid eye drops: can mask signs of infection, delaying healing. - Anticholinergic ocular agents: may reduce tear production, worsening discomfort.